Chong Kun Dang to introduce novel ulcerative colitis medication from US-based Salix Pharmaceuticals

Chong Kun Dang Pharmaceuticals said it recently signed with the U.S.-based Salix Pharmaceuticals (Dr. Lorin Johnson, a co-founder of Salix), a leading pharmaceutical firm in the sales/marketing of digestive drugs, an exclusive distribution agreement for the marketing of Colazal (balsalazide disodium), a novel drug for the treatment of mild to moderate ulcerative colitis.

Colazal was approved...